ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity, anti-infectives, metabolism, and cancer. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidate includes IPP-204106, a peptide to modulate angiogenesis with application in cancer and ophthalmology; and BioGlucagon a therapy for low sugar events in diabetes. ImmuPharma plc has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists, as well as development of peptides as glucagon antagonists to treat type I and type II diabetes; and license and development agreement with Avion Pharmaceuticals LLC. The company was founded in 1999 and is headquartered in London, the United Kingdom.